KURA at a glance
Kura Oncology, Inc. (KURA, SEC CIK 1422143) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 9, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Kura Oncology, Inc. (KURA) shares worth $389.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Powl Brian T. on September 29, 2026 of 15,430 shares at $10.75 per share.
- In the last 90 days, KURA insiders reported 2 open-market purchases ($2.4M) and 12 open-market sales ($1.7M) on Form 4, a net purchase of $643K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $67.5M
- +25.2% vs prior year
- Insiders · 90 days
- 2 buys · 12 sells
- Net +$643K
- 13F holders
- 27 funds
- $389.6M · +0 vs prior quarter
- Latest 8-K
- Sep 9, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered commercialization risk: KOMZIFTI became FDA-approved in November 2025, creating first-product launch and market-acceptance exposure
- Most material update: post-approval safety data could change KOMZIFTI’s label or trigger withdrawal from the market
- Regulatory risk: FDA approval remains subject to continual review covering manufacturing, promotion, labeling and distribution
- Competitive risk: KOMZIFTI faces REVUFORJ, another FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated AML
- Reimbursement risk: HHS Medicare drug-price negotiations could significantly reduce reimbursement for selected single-source drugs
AI summary of the KURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus
- Kura invested $4.3M and retains approximately 49.2% ownership, preserving substantial economic exposure without majority control
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jennifer Fulk appointed CFO, principal financial officer and principal accounting officer effective September 8, 2026
- Replaces Troy E. Wilson as principal financial officer and Thomas Doyle as principal accounting officer
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
Item EX-99.1: Item EX-99.1
- KOMZIFTI revenue reached $9.1M, up 57% sequentially, with approximately 115 new patient starts, up 35%
- Majority share of new starts in R/R NPM1-mutated AML supports early commercial leadership after two full launch quarters
AI summaries of KURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KURA
Don't miss the next KURA filing
- Alerts as it files. A push when KURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KURA, by share count.
- Ask anything. An AI agent that reads every KURA filing and answers with sources.
KURA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Powl Brian T. | Sell | Sep 29, 2026 | 15,430 | $10.75 |
| Leoni Mollie | Sell | Sep 29, 2026 | 28,802 | $10.75 |
| FORD KATHLEEN | Sell | Sep 29, 2026 | 3,668 | $10.75 |
| Bair Teresa Brophy | Sell | Sep 28, 2026 | 8,442 | $10.50 |
| DOYLE THOMAS JAMES | Sell | Sep 28, 2026 | 4,607 | $10.50 |
| Powl Brian T. | Sell | Sep 28, 2026 | 8,000 | $10.56 |
| FORD KATHLEEN | Sell | Sep 28, 2026 | 6,906 | $10.50 |
| Leoni Mollie | Sell | Sep 28, 2026 | 12,448 | $10.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $53.9M | $67.5M |
| Operating Income | -$165.8M | -$193.2M | -$303.6M |
| Net Income | -$152.6M | -$174.0M | -$278.7M |
| Op. Margin | - | -358.5% | -449.9% |
| Net Margin | - | -322.9% | -412.9% |
| Balance Sheet | |||
| Total Assets | - | $760.2M | $738.4M |
| Equity | - | $413.6M | $174.1M |
| ROE | - | -42.1% | -160.0% |
| Per Share | |||
| EPS | $-2.08 | $-2.02 | $-3.18 |
| Cash Flow | |||
| Operating CF | - | $134.3M | -$64.1M |
| CapEx | - | $472K | $6.6M |
Source: XBRL data in Kura Oncology, Inc. (KURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $389.6M |
| Q1 2026 | 27 | $263.7M |
| Q4 2025 | 24 | $356.7M |
| Q3 2025 | 25 | $293.5M |
| Q2 2025 | 26 | $172.3M |
| Q1 2025 | 22 | $131.9M |
| Q4 2024 | 18 | $155.0M |
| Q3 2024 | 15 | $177.5M |
- AQR Capital Management+1.00M (+47%)
- BlackRock+871.7K (+9%)
- Goldman Sachs Group+831.7K (+58%)
- State Street Corp+817.3K (+18%)
- Prudential Financial+226.7K (+549%)
- Millennium Management−853.8K (-55%)
- Dimensional Fund Advisors−256.8K (-18%)
- Two Sigma Investments−190.4K (-53%)
- Bank of America Corp−69.2K (-6%)
- Citadel Advisors LLC−40.7K (-11%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KURA SEC filings: frequently asked questions
Are KURA insiders buying or selling?
In the last 90 days, Kura Oncology, Inc. (KURA) officers, directors and 10% owners reported 2 open-market purchases worth $2.4 million by 1 insider and 12 open-market sales worth $1.7 million by 6 insiders on Form 4, a net purchase of $642,959. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KURA stock?
As of June 30, 2026, the largest Kura Oncology, Inc. (KURA) holders among the 13F filers tracked by SignalX were BlackRock ($115.3 million), State Street Corp ($58.5 million), Vanguard Capital Management LLC ($43.0 million), AQR Capital Management ($34.3 million), Goldman Sachs Group ($24.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KURA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Kura Oncology, Inc. (KURA) reported revenue of $67.5 million (up 25.2% from FY2024) and a net loss of $278.7 million. Diluted EPS was -$3.18. The figures come from the XBRL data in the 10-K.
What did KURA report in its latest 8-K?
Kura Oncology, Inc. (KURA) filed an 8-K on September 9, 2026 reporting Item 8.01 (Other Events). Caspian raised $50.0M in Series A financing, funding cardiometabolic development outside Kura’s core oncology focus.
What are the latest KURA SEC filings?
Kura Oncology, Inc. (KURA) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 9, 2026 and a Form 4 insider filing on September 29, 2026.
What is KURA's SEC CIK number?
Kura Oncology, Inc. (KURA)'s SEC Central Index Key (CIK) is 1422143. EDGAR lists every KURA filing under that number.
Ask anything about KURA
The research agent reads KURA's filings, financials, insider trades and 13F holders, then answers with sources.